A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)

Trial Profile

A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 14 Apr 2018 Results assessing the mechanism of action of Seladelpar in PBC and NASH patients from phase II studies (NCT00701883, NCT02472535, NCT02609048 and NCT02955602) presented at The International Liver Congress 2018
    • 10 Jun 2017 Biomarkers information updated
    • 11 May 2016 Results will be presented at the 84th European Atherosclerosis Society (EAS) Congress 2016, according to a CymaBay media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top